Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis
Embodiments of screening methods for determining test agents effective for modifying the appearance of pigmented skin are provided. The screening method may comprise the steps of contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADRβ1 receptors, and determining based on the binding interaction of the test agent with the ADRβ1 receptors whether the test agent is an effective ADRβ1 receptor antagonist suitable for modifying the appearance of pigmented skin, wherein a test agent is considered to be an effective ADRβ1 receptor antagonist when it defines a half maximal inhibitory concentration of less than about 1000 ppm.
1. A screening method for determining whether a test agent, which is suitable for use in a topical cosmetic composition, is effective for modifying the appearance of pigmented skin, the method comprising:
contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADRβ1 receptors and wherein the test agent is a cosmetic agent; and
determining based on the binding interaction of the test agent with the ADRβ1 receptors whether the test agent is an effective ADRβ1 receptor antagonist suitable for modifying the appearance of pigmented skin, wherein the test agent is considered to be an effective ADRβ1 receptor antagonist when it defines a half maximal inhibitory concentration of less than about 1000 ppm.
2. The screening method of claim 1 wherein the ADRβ1 receptor antagonists also act as antagonists of the ADRβ2 receptors.
3. The screening method of claim 1 further comprising contacting a second cell, a second cell culture, or a second set of bulk cells with the test agent and determining the test agent as effective for modifying the appearance of pigmented skin if the test agent is an antagonist of the ADRβ2 receptors.
4. The screening method of claim 1 , further comprising evaluating the test agent in a melanin synthesis assay selected from the group consisting of a B16 cell assay or a skin model.
5. The screening method of claim 1 wherein the test agent identified as an ADRβ1 receptor antagonist defines a half maximal inhibitory concentration of less than about 100 ppm.
6. The screening method of claim 1 wherein the test agent identified as an ADRβ1 receptor antagonist defines a half maximal inhibitory concentration of less than about 50 ppm.
7. A screening method for determining at least one test agent as effective for modifying the appearance of pigmented skin, the method comprising:
contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADRβ3 receptors; and
determining based on the binding interaction of the test agent with the ADRβ3 receptors whether the test agent is an ADRβ3 receptor agonist suitable for modifying the appearance of pigmented skin.
8. A screening method for determining at least one test agent as effective for modifying the appearance of pigmented skin, the method comprising:
contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADRα1B receptors;
determining based on the binding interaction of the test agent with the ADRα1B receptors whether the test agent is an ADRα1B receptor antagonist suitable for modifying the appearance of pigmented skin.
9. A screening method for determining at least one test agent as effective for modifying the appearance of pigmented skin, the method comprising:
contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADRα2C receptors;
determining based on the binding interaction of the test agent with the ADRα2C receptors whether the test agent is an ADRα2C receptor antagonist suitable for modifying the appearance of pigmented skin.